

Open Peer Review on Qeios

Smoothened Antagonist LDE225 Topical

National Cancer Institute

Source

National Cancer Institute. <u>Smoothened Antagonist LDE225 Topical</u>. NCI Thesaurus. Code C88337.

A topical formulation of the small-molecule Smoothened (Smo) antagonist LDE225 with potential antineoplastic activity. Upon topical application, smoothened antagonist LDE225 selectively binds to the Hedgehog (Hh)-ligand cell surface receptor Smo, which may result in the suppression of the Hh signaling pathway and, so, the inhibition of tumor cells in which this pathway is abnormally activated. The Hh signaling pathway plays an important role in cellular growth, differentiation and repair. Inappropriate activation of Hh pathway signaling and uncontrolled cellular proliferation, as is observed in a variety of cancers, may be associated with mutations in the Hh-ligand cell surface receptor Smo.

Qeios ID: DG2WQG · https://doi.org/10.32388/DG2WQG